STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Investor Presentation (June 2019)
28 slides from STRATA Skin Sciences's investor presentation, Jun 10, 2019
Slide 1: June 2019 Investor Presentation
June 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients with Clinics
Slide 2: Safe Harbor Statement
This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking s
Slide 3: STRATA Investment Highlights
STRATA Investment Highlights 3 A Win-Win-Win CompanyFor patients – safest, most effective, no side effectsFor clinics – stable increased revenue baseFor Payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis and Leuk
Slide 4: The Market Opportunity
The Market Opportunity Over 35 million domestic and 100 million Global potential patients$6 Billion domestic opportunityEstablished reimbursement rate$150-$250 reimbursement based on body surface area affected - 3 Excimer specific CPT Codes (96920, 96921, 96922) Average of 23 treatments per patient
Slide 5: Excimer laser use grew at ~30% annual rate in the US
Excimer laser use grew at ~30% annual rate in the US over last 15 years 5 Historical phototherapy utilization. Trend in phototherapy utilization among Medicare beneficiaries by billing code across all providers, 2000 to 2015. HCPCS, Healthcare Common Procedure Coding System; PUVA, psoralen plus ultr
Slide 6: Continuous technology investment and business growth
Continuous technology investment and business growth 510 (K) FDA Approval AL-7000 Ultra Velocity 400 Velocity 700 Velocity 7 Series S3 2000 2005 2008 2010 2014 2018 CPT code Approval DTC platform creation 510 (K) FDA Approval (MMD)* Full Insurance Reimbursement 2012 *MMD tip is a diagnostic accessor
Slide 7: XTRAC is to excimer what Xerox is to photocopy
XTRAC is to excimer what Xerox is to photocopy Over 150 peer-reviewed published clinical-studiesMultiple academic institutes in U.S. use XTRAC Over 2,000 device installed base worldwideOver 1,000 dermatology practices in the U.S have XTRAC providing device access to over 3,000 dermatology providers
Slide 8: Partner academic institutes
Partner academic institutes 8
Slide 9: How XTRAC Works - Psoriasis
How XTRAC Works - Psoriasis After 4 tx After 2 tx Baseline Beam of UVB light applied to the affected area UVB light induces apoptosis of the keratinocytes and T cells in the dermis Promotes immunosuppression Induces alterations in cytokine profile 150+ peer reviewed published clinical studies 9 PASI
Slide 10: How XTRAC Works - Vitiligo
How XTRAC Works - Vitiligo 10 Long-term skin condition characterized by patches of skin losing its pigment Disease is believed to be due to genetic susceptibility where the autoimmune disease is then triggeredPotentially the immune system is attacking and destroying melanocytes of the skinLife-alter
Slide 11: XTRAC Revenue Funnel
XTRAC Revenue Funnel 8n6 Protocol Treatment *RDX – Reimbursement Database XTRAC (proprietary system) REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN WIN WIN DOCTOR PATIENT STRATA (AND PAYER) INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY VERIFY APP
Slide 12: DTC advertisement generating word of mouth for XTRAC
DTC advertisement is generating word of mouth for XTRAC through ‘Shares’ and ‘Comments’ 12
Slide 13: Lead Generation is a Business Driver
Lead Generation is a Business Driver Patient leads in one quarterLeads turn into appointmentsAppointments lead to XTRAC partner revenueOther revenue for the partner clinicRevenue for STRATA 13 NYC, NJ, Long Island
Slide 14: International Market: Installed Base
International Market: Installed Base OUS sales are through distribution with no current recurring revenue model appliedMajor Markets – China, Japan, Saudi Arabia, South KoreaInsurance covered in most marketsUsage/device higher than domestic market – untapped potential in U.S.1,300 OUS devices sold a
Slide 15: Maximizing Dermatologist Partner Clinical Revenue
Maximizing Dermatologist Partner Clinical Revenue Data collected directly from the lasers demonstrates the importance of following treatment guidelines Revenue = # of lasers x # of treatments/pt x # patients x cost/tx x recurrence factor 15
Slide 16: XTRAC creates significant recurring revenue for the partners
XTRAC creates significant recurring revenue for the partners CPT CODE Description 2018 National AverageMedicare Payment Rate 96920 Laser treatment for inflammatory skin diseases, (psoriasis); total area less than 250 sq cm $168.12 96921 Laser treatment for inflammatory skin diseases, (psoriasis); to
Slide 17: Domestic Market: Installed Base Overview
Domestic Market: Installed Base Overview 754 Partner XTRAC clinics 150+ sold XTRAC 4 Regions 24 Sales Territories 15 Field Service Techs In-house call center to qualify leadsOnly one competitor in U.S. 17 Territories color coded
Slide 18: Proven Turnaround Strategy – Install Base and Utilization Growth
Proven Turnaround Strategy – Install Base and Utilization Growth * STRATA bought XTRAC business from PhotoMedex in 2015 18 Note the numbers prior to Jan 1, 2018 do not reflect adjustments for the adoption of ASC 606 Q1 ’19 average revenue - 16% growth over Q1 ‘18
Slide 19: DTC – The Driver for Recurring Revenue Growth
DTC – The Driver for Recurring Revenue Growth 19 Q1 ’19 qtr. revenue - 17% growth over Q1 ‘18 * STRATA bought XTRAC business from PhotoMedex in 2015 Note the numbers prior to Jan 1, 2018 do not reflect adjustments for the adoption of ASC 606
Slide 20: Install Base Growth Drivers
Install Base Growth Drivers 20 1,570 clinics owned by 58 roll-up groups151 (9.5%) of which are XTRAC partnersStrata signs strategic expansion agreements with major groups Expansion into roll-up groups Comebacks 300-400 Clinics own Excimer lasers Conversion to an XTRAC partner clinic = immediate reve
Slide 21: Recent Financial Highlights
Recent Financial Highlights Q1 2019Q4 2018Q3 2018 21 Total Revenue $7.9 million +8% versus Q3 2017 Recurring XTRAC Revenue $5.6 million +1% versus Q3 2017 Gross Margin 61% +6% versus Q3 2017 Dermatology Recurring Procedures Revenue Margin 68% +6% versus Q3 2017 Cash and Cash Equivalents $15.9 millio
Slide 22: Financial Profile
Financial Profile Shares and Share Equivalents – Market cap*- $77M (As of June 4, 2019) * On an as converted basis of the convertible preferred stock** Does not include 2.1M warrants with a weighted average exercise price of $5.41 as of March 31, 2019 of which 1.4M expire by July 2019** Does not inc
Slide 23: STRATA Investment Highlights
STRATA Investment Highlights 23 A Win-Win-Win CompanyFor patients – safest, most effective, no side effectsFor clinics – stable increased revenue baseFor Payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis and Leu
Slide 24: June 2019 Driving Value to Dermatology Partners
June 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients with Clinics 24
Slide 25: Appendix
Appendix 25
Slide 26: XTRAC helps patients Live Clear, Live Free
XTRAC helps patients Live Clear, Live Free… https://youtu.be/GdMBliZYy70 26
Slide 27: Sample studies from 150+ clinical studies
Multicenter Psoriasis Study1 Scalp Study3 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or bet
Slide 28: Financial Metrics
Financial Metrics 28 Note: all quarterly numbers are unaudited
STRATA Skin Sciences — Investor Presentation (June 2019) on 6ix